Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma.
Robert Hans Ingemar Andtbacka(University of Utah), Kenneth F. Grossmann(University of Utah), Hung T. Khong(University of Utah), Adil Daud(University of California, San Francisco), Matthew H. Taylor(Providence Portland Medical Center), Aislyn Boran(Daiichi Sankyo (United States)), John T. Vetto(Oregon Health & Science University), Richard S. Ungerleider(Unknown), Merrick I. Ross(Johns Hopkins University), Sanjiv S. Agarwala(Goethe University Frankfurt), Maki Tanaka(Takara (Japan)), Rogerio I. Neves(Saint John's Health Center)
Cited by 19
Related Papers
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
|Nature Medicine|2018|1k
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
|Immunity|2018|937
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914